When are drug-eluting stents effective? A critical analysis of the presently available data;Wann sind drug-eluting stents als wirksam zu bezeichnen? Eine kritische analyse der aktuellen datenlage

Zeitschrift fur Kardiologie

Volumn 93, Issue 9, 2004, Pages 649-663

  Silber, Sigmund ^a  

^a Kardiologische Praxis und Praxisklinik   (Germany)

Author keywords

Drug eluting stents; Paclitaxel; PCI; Restenosis; Sirolimus

Indexed keywords

ABCIXIMAB; ABT 578; ANGIOPEPTIN; ANTIINFLAMMATORY AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; AVI 4126; BATIMASTAT; BIOLIMUS; CYCLOSPORIN; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; EVEROLIMUS; METHOTREXATE; MITOMYCIN; MYC PROTEIN; PACLITAXEL; POLYMER; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SIROLIMUS; STENTS; TERMINOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 4644317869     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-004-0143-8     Document Type: Review

References (101)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780
2. Silber S (2002) Antiproliferativ beschichtete Stents und intrakoronare Brachytherapie: Gemeinsamkeiten und Unterschiede. Z Kardiol 91:443-457
3. Sousa JE, Serruys PW, Costa MA (2003) New frontiers in cardiology: drug-eluting stents: Part I. Circulation 107:2274-2279
4. Sousa JE, Serruys PW, Costa MA (2003) New frontiers in cardiology: drug-eluting stents: Part II, Circulation 107:2383-2389
5. Babapulle MN, Eisenberg MJ (2002) Coated stents for the prevention of restenosis: Part I. Circulation 106:2734-2740
6. Babapulle MN, Eisenberg MJ (2002) Coated stents for the prevention of restenosis: Part II. Circulation 106: 2859-2866
7. Serruys PW (1995) Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis. Circulation 92:2759-2760
8. Armstrong J, Gunn J, Armold N, Malik M, Chan KH, Vick T, Stratford P, Cumberland DC, Holt CM (2002) Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. J Invasive Cardiol 14: 230-238
9. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780-786
10. Kipshidze NN, Kim HS, Iversen P, Yazdi HA, Bhargava B, New G, Mehran R, Tio F, Haudenschild C, Dangas G, Stone GW, Iyer S, Roubin GS, Leon MB, Moses JW (2002) Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 39:1686-1691
11. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, Bruining N, Sabate M, Serruys PW (2002) Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 39:281-287
12. New G, Moses JW, Roubin GS, Leon MB, Colombo A, Iyer SS, Tio FO, Mehran R, Kipshidze N (2002) Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Interv 57:266-271
13. Huang Y, Salu K, Liu X, Li S, Wang L, Verbeken E, Bosmans J, De Scheerder I (2003) Local stent-mediated methotrexate delivery reduces neointimal hyperplasia in a porcine coronary model. Am J Cardiol 92(Suppl 6A): 21L
14. Abizaid A, Albertal M, Costa MA, Abizaid AS, Staico R, Feres F, Mattos LA, Sousa AG, Moses J, Kipshidize N, Roubin GS, Mehran R, New G, Leon MB, Sousa JE (2004) First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 43:1118-1121
15. Wessely R, Jaschke B, Wegener F, Milz S, Schömig A (2003) Statins are promising compounds for drug coated stents to prevent restenosis following percutaneous coronary intervention. Eur Heart J 24:(Abstr):426
16. Klein N, Mende M, Rother T, Neugebauer A, Pfeiffer D (2003) Trapidil eluting coronary stent: protection from restenosis without cellular toxicity? Eur Heart J 24:(Abstr):420
17. Kaluza GL, Granada JF, Schulz DG, Raizner AE (2003) Evaluation of vascular effects of simvastatin-eluting stents in porcine coronary arteries at 1 month postimplantation. Am J Cardiol 92(Suppl 6A):22L
18. Kim W, Jeong MH, Jang YS, Hong YJ, Lee SH, Park OY, Park WS, Kim JH, Kim IS, Choi MJ, Ahn YK, Cho JG, Park JC, Cho DL, Kang JC (2003) The first clinical experience with a reopro-coated coronary stent. Am J Cardiol 92(Suppl 6A):182L
19. Kim W, Jeong MH, Cha KS, Lee SH, Hong YJ, Ahn YK, Cho JG, Park JC, Kang JC (2003) Carvedilol-coated coronary stent prevents porcine coronary stent restenosis. Am J Cardiol 92(Suppl 6A):181L
20. Van Alstine WG, Ragheb AO, Machan LS (2003) One month safety of nonpolymeric paclitaxel coated nitinol stents in the porcine Aorta. Am J Cardiol 92(Suppl 6A):23L
21. Trabattoni D, Antoniucci D, Fabbiocchi F, Valenti R, Montorsi P, Migliorini A, Lualdi A, Parodi G, Novellini E, Bartorelli AE (2003) First clinical experience with the tacrolimus-eluting janus carbostent in de novo coronary arteries: the jupiter I study. Am J Cardiol 92(Suppl 6A):60L
22. Finkelstein A, McClean D, Kar S, Takizawa K, Varghese K, Baek N, Park K, Fishbein MC, Makkar R, Litvack F, Eigler NL (2003) Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107:777-784
23. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, Michaeli W, Weber C, Blindt R (2003) A novel biodegradable coronary polymer stent with drug-delivery capacities: paclitaxel-loading inhibits neointimal hyperplasia in a porcine model of coronary restenosis. EHJ 24:(abstr):426
24. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T, Nakamura T, Fujita S, Takeda S, Motohara S, Uehata H (2003) Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 5:13-16
25. Grube E, Lansky AJ, Reifart N, Fajadet N, DiSciascio G, DiMario C, Hauptmann K, Colombo A, Bach R, Silber S, for the SCORE investigators, SCORE Six-Month Angiographic Results (2002) Improved restenosis in patients receiving the QUADDS-QP2 drug-eluting stent compared with the control, bare stents. JACC 39:59A
26. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, Lansky AJ, Stertzer SH, Yock PG, Fitzgerald PJ (2002) 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the study to Compare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 106:1788-1793
27. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S, Montorfano M, Carlino M, Briguori C, Pagnotta P, Albiero R, Corvaja N, Colombo A (2002) First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for instent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105:1883-1886
28. Silber S, Grube E, Fitzgerald P, The Quanam QUADDS-QP2 Stent (2001) Book chapter. In: Serruys P, Kutryk M (eds) Handbook of coronary stents, 4th edition. Martin Dunitz Publishers LtD, pp 343-347
29. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A (2002) Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106:2649-2651
30. Mudra H, Bode C, Grube E, De Haan F, Levenson B, Schuler G, Silber S (2004) Positionspapier zum Einsatz von Medikamente freisetzenden Stents bei Patienten mit koronarer Herzerkrankung. Z Kardiol 93:416-422
31. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS (2003) A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348:1537-1545
32. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW (2004) Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109:487-493
33. Heldman AW, Farhat N, Fry E, Cummins F, Roubin G, Mc Garvery J, Raizner AE, Voorhees WD, Fearnot N (2002) Paclitaxel-eluting stent for cytostatic prevention of restenosis: patency study follow-up. Am J Cardiol 90(Suppl 6A):3H
34. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME (2003) TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42
35. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788-794
36. Schofer J, Schlüter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G, and E-SIRIUS Investigators, Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries (2003) Double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093-1099
37. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43:1110-1115
38. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ (2004) Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109:2168-2171
39. Grube E, Buellesfeld L, Mueller R, Staberock M, Schmidt T, Selbach G, Gerckens U (2003) Everolimus stent coating: promising procedural and 6-month angiographic and intravascular ultrasound follow-up results of the FUTURE I and II trial. EHJ 24:267
40. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW (2004) Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109:1948-1954
41. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231
42. Grube E (2004) TAXUS VI: Presentation of the trial and clinical outcomes. EuroPCR Paris, late breaking trials
43. Dawkins K (2004) TAXUS VI: Angiographic results and QCA analysis. EuroPCR Paris, late breaking trials
44. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323
45. Gunn J, Cumberland D (1999) Stent coatings and local drug delivery; state of the art. Eur Heart J 20:1693-1700
46. Kastrati A, Schömig A, Dirschinger J, Mehilli J, von Welser N, Pache J, Schühlen H, Schilling T, Schmitt C, Neumann FJ (2000) Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 101:2478-2483
47. Leon MB, Holmes DR, Simonton C, Moses JW, O'Shaughnessy C, Caputo RP, Wong SC, Buchbinder M, Chapman G, KR E (2003) The impact of sirolimus-eluting stents in diabetics: results from the SIRIUS trial. J Am Coll Cardiol 41(Suppl A):54A
48. Silber S (2003) Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3319 patients. J Interv Cardiol 16:485-490
49. Liu X, Huang Y, Hanet C, Vandormael M, Legrand V, Dens J, Vandenbossche JL, Missault L, Vrints C, De Scheerder I (2003) Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 60:172-178
50. De Scheerder I, Chevalier B, for the Brilliant-I Investigators, Experimental and Preliminary Clinical Results with Batimastat (2002) Drug-eluting stents satellite symposium. Atlanta, USA
51. Meredith I, ENDEAVOR-I (2004) EuroPCR Paris, late breaking trials
52. Silber S, Grube E, Marco J, Grollier G, Morice MC, Serruys P, Cobaugh M, Wijns W (2003) Direct stent implantation using the EXPRESS coronary stent system: results of a multicenter feasibility study. J Interv Cardiol 16:491-497
53. Silber S, Grube E (2001) The Boston Scientific Antiproliferative, Paclitaxel Eluting Stents (TAXUS). Book chapter in: handbook of coronary stents, 4th edition. Serruys P, Kutryk M (eds) Martin Dunitz Publishers LtD 311-319
54. Dambrin C, Klupp J, Birsan T, Luna J, Suzuki T, Lam T, Stahr P, Hausen B, Christians U, Fitzgerald P, Berry G, Morris R (2003) Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation 107:2369-2374
55. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N, Soon-Shiong P, Virmani R (2002) Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 106:1195-1198
56. Marks AR (2003) Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 349:1307-1309
57. Sonoda S, Honda Y, Kataoka T, Bonneau HN, Sudhir K, Yock PG, Mintz GS, Fitzgerald PJ (2003) Taxol-based eluting stents from theory to human validation: clinical and intravascular ultrasound observations. J Invasive Cardiol 15:109-114
58. Hodgson JM, Bottner RK, Klein LW, Walpole HT Jr, Cohen DJ, Cutlip DE, Fenninger RB, Firth BG, Greenberg D, Kalisky I, Meskan T, Powell W, Stone GW, Zito JP, Clark MA (2004) Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. Catheter Cardiovasc Interv 62:1-17
59. Silber S, Albertsson P, Avilés FF, Camici P, Colombo A, Hamm C, Joergensen JE, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone G, Wijns W (2004) European guidelines for Percutaneous Coronary Interventions (PCI). Eur Heart J (in press)
60. NICE (National Institute for Clinical Excellence) (2004) Coronary artery stents (No 71), (replacing Drug-eluting stents No 4). http://www.nice.org.uk
61. Moreno R, Fernandez C, Alfonso F, Hernandez R, Perez-Vizcayno MJ, Escaned J, Sabate M, Banuelos C, Angiolillo DJ, Azcona L, Macaya C (2004) Coronary stenting versus balloon angioplasty in small vessels. A meta-analysis from 11 randomized studies. J Am Coll Cardiol 43:1964-1972
62. Ardissinio D, Cavallini C, Bramucci E, Marzocchi A, Indolfi C, Manari A, Mongiardo R, Violini R (2004) A randomized comparison of a sirolimus-eluting stent and a standard stent in the prevention of restenosis in small coronary arteries: the SES-SMART trial. Late-Breaking Clinical Trials, presented at the Annual ACC Scientific Session, New Orleans, USA
63. Lemos PA, Arampatzis CA, Saia F, Hoye A, Degertekin M, Tanabe K, Lee CH, Cummins P, Smits PC, McFadden E, Sianos G, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW (2004) Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry). Am J Cardiol 93:633-636
64. Sousa E, SVELTE (2004) EuroPCR Paris, late breaking trials
65. Lansky AJ, Dangas G, Mehran R, Desai KJ, Mintz GS, Wu H, Fahy M, Stone GW, Waksman R, Leon MB (2002) Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. J Am Coll Cardiol 39:274-280
66. Urban P, Serruys P, Baumgart D, Colombo A, Silber S, Eeckhout E, Gershlick A, Wegscheider K, Verhees L, Bonan R (2003) A multicentre european registry of intraluminal coronary beta brachytherapy. Eur Heart J 24:604-612
67. Silber S (2002) Intrakoronare Strahlentherapie in kontrollierten und offenen Studien mit Afterloading-Systemen und "heißen" Ballonkathetern. Eine Analyse von 6692 Patienten. Herz 27:30-55
68. Leon MB, Popma JJ, Yakubov S, Bachinsky W, Teirstein PS, Fischell TA, Satler L, Reisman M, Moses JW (2003) The effects of sirolimus-eluting stents on in-stent and peri-stent restenosis: an angiographic subanalysis from the SIRIUS trial. JACC 41(Suppl A):14A
69. O'Neill W, Popma JJ, Kuntz RE, Snead D (2003) Elimination of margin restenosis with sirolimus-eluting stents. Am J Cardiol 92(Suppl 6A): 58L
70. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Weissman NJ, Fearnot NE, Park SW, Park SJ (2003) Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 107:517-520
71. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC (2002) Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 106:798-803
72. West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neill WW, Mercado NF, Serruys PW (2004) Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 109:867-873
73. Loutfi M, Mulvihill NT, Boccalatte M, Farah B, Fajadet J, Marco J (2003) Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Catheter Cardiovasc Interv 58: 451-454
74. Serruys PW, S IJ, Hout B, Vermeersch P, Bramucci E, Legrand V, Pieper M, Antoniucci D, Gomes RS, Macaya C, Boekstegers P, Lindeboom W (2003) Direct stenting with the Bx VELOCITY balloon-expandable stent mounted on the Raptor rapid exchange delivery system versus predilatation in a European randomized Trial: the VELVET trial. Int J Cardiovasc Intervent 5:17-26
75. Silber S, Hamburger J, Grube E, Pfisterer M, Belardi J, Webb J, Zmudka K, Nienaber C, Hauptmann K, Rutsch W, Dawkins K, Drzewiecki J, Koglin J, Colombo A (2004) Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation: a post hoc analysis of TAXUS II. Herz 29:171-180
76. Schofer J (2003) Sirolimus-eluting stent in long lesions: direct stenting versus predilatation (E-SIRIUS). Hotline II, Jahrestagung der Europäischen Gesellschaft für Kardiologie (ESC), Wien
77. Moses JW, Leon MB, Popma JJ, Cohen SA, Kuntz R (2004) Matched comparison of direct stenting to predilatation with the sirolimus-eluting bx velocity stent. J Am Coll Cardiol 43(Suppl A):97A
78. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ (2004) Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109:190-195
79. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, Liistro F, Carlino M, Airoldi F, Chieffo A, Di Mario C (2003) Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 107:2178-2180
80. Loutfi M, Sauguet A, Silveira J, Farah B, Fajadet J, Marco T (2003) Drug-eluting stent failure: a challenging new therapeutic problem. Am J Cardiol 92(Suppl 6A):56L
81. Orlic D, Bonizzoni E, Stankovic G, Airoldi F, Chieffo A, Corvaja N, Sangiorgi G, Ferraro M, Briguori C, Montorfano M, Carlino M, Colombo A (2004) Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol 43:1154-1160
82. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW (2003) Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 108:257-260
83. Hwang CW, Wu D, Edelman ER (2003) Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent 5:7-12
84. Lemos PA, Van Mieghem CA, Arampatzis CA, Hoye A, Ong AT, McFadden E, Sianos G, Van der Giessen WJ, De Feyter PJ, Van Domburg RT, Serruys PW (2004) Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention. Late Angiographic and Clinical Outcomes. Circulation 109:2500-2502
85. Virmani R, Kolodgie FD, Farb A, Lafont A (2003) Drug eluting stents: are human and animal studies comparable? Heart 89:133-138
86. Dietz R, Silber S, Baumgart D, Hehrlein C, Tebbe U (2001) Positionspapier zur intrakoronaren Brachytherapie. Z Kardiol 90:875-880
87. Pasceri V, Granatelli A, Pristipino C, Pelliccia F, Pironi B, Richichi G (2003) High-Risk of thrombosis of cypher stent in patients not taking ticlopidine or clopidogrel. Am J Cardiol 92(Suppl 6A):91L
88. Degertekin M, Regar E, Tanabe K, Lemos P, Lee CH, Smits P, de Feyter P, Bruining N, Sousa E, Abizaid A, Ligthart J, Serruys PW (2003) Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound. Am J Cardiol 91:1046-1050
89. Leon MB, Moses JW, Weisz G, Teirstein PS, Fitzgerald PJ, Holmes DR, Popma JJ (2003) The frequency and consequences of angiographic aneurysms after sirolimus-eluting stents: results from SIRIUS. J Am Coll Cardiol 41(Suppl A):13A
90. Lemos PA, Serruys PW, Sousa JE (2003) Drug-eluting stents: cost versus clinical benefit. Circulation 107: 3003-3007
91. O'Neill WW, Leon MB (2003) Drug-eluting stents: costs versus clinical benefit. Circulation 107:3008-3011
92. Griffiths H, Bakhai A, West D, de Souza A, Clague JR, Davies SW, Brookes CI, Bishop AJ, Pepper J, Di Mario C (2003) Stents without restenosis: enough to replace bypass surgery? Am J Cardiol 92(Suppl 6A):59L
93. Poyen V, Silvestri M, Labrunie P, Valeix B (2003) Indications of coronary angioplasty and stenting in 2003: what is left to surgery? J Cardiovasc Surg (Torino) 44:307-312
94. Ferreira AC, Peter AA, Salerno TA, Bolooki H, de Marchena E (2003) Clinical impact of drug-eluting stents in changing referral practices for coronary surgical revascularization in a tertiary care center. Ann Thorac Surg 75:485-489
95. Fattori R, Piva T (2003) Drug-eluting stents in vascular intervention. Lancet 361:247-249
96. Werner GS, Schwarz G, Emig U, Betge S, Krack A, Figulla H (2004) Paclitaxel-freisetzende Stents zur Verhinderung von Restenose und Reokklusion nach Rekanalisation chronischer Koronarverschlüsse (PACTO-Studie) 93(Suppl 3):III-187(Abstr)
97. Lotan C, Almagor Y (2004) SICTO. EuroPCR Paris, late breaking trials
98. Hoye A, Tanabe K, Lemos P, Aoki J, Saia F, Arampatzis CA, Degertekin M, Hofma S, Sianos G, Mc Fadden EP, van der Giessen W, Smits PC, de Feyter P, van Domburg R, Serruys P (2004) Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 43:1954-1958
99. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB (2004) Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109:1244-1249
100. Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, Lee CH, Ruiter A, McFadden E, Sianos G, Smits PC, van der Giessen WJ, de Feijter P, van Domburg R, Serruys PW (2003) Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol 92:327-329
101. Serruys P (2004) ARTS II - First clinical results. EuroPCR Paris, late breaking trials